Johnson & Johnson welcomes the New Zealand Government’s announcement to dedicate an additional $604m to bring much needed
innovative cancer medicines to New Zealand patients.
“There is currently a significant unmet need in a range of cancer treatment options,” Hayden Paul, Commercial Lead,
Johnson & Johnson New Zealand said.
“J believes this week’s announcement is a positive sign for the thousands of patients who are waiting for access to
medicines. We trust the Government will act swiftly to finalise access to these new medicines for cancer treatment.
“New Zealand has long been a challenging environment for medicines access and for medicines businesses. This
announcement offers the possibility for increased business confidence and could support increased investment and jobs
for New Zealand’s future.”